advances-in-protein-chemistry

56. Yonemura Y, Endo Y, Fujita H, Kimura K, Sugiyama K, et al. (2001) Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific
antisense oligonucleotide. J Exp Clin Cancer Res 20: 205-212.
57. Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, et al. (2000) Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells
by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 60: 6851-6855.
58. Noonberg SB, Benz CC (2000) Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs
59: 753-767.
59. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, et al. (1999) Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis
by halofuginone. Clin Cancer Res 5: 1982-1988.
60. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA (2001) Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic
molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci U S A 98: 119-124.
61. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH (2000) Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.
Cancer Res 60: 6061-6067.
62. Jiang Y, Wang M, Celiker MY, Liu YE, Sang QX, et al. (2001) Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix
metalloproteinase 4 gene delivery. Cancer Res 61: 2365-2370.
63. Moore MJ et al. (2002) A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12–9566 (9566) in patients
(PTS) with advanced pancreatic cancer. ASCO Online.
64. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93: 178-193.
65. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, et al. (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17: 768-774.
66. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, et al. (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an
early event in the formation of bone metastases. Cancer Res 60: 2949-2954.
67. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E (2001) Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III
clinical trials. Semin Oncol 28: 620-625.
68. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R, et al. (1999) Tumor invasion: molecular shears blunted by green tea. Nat Med 5: 1216.
69. Jiang MC, Liao CF, Lee PH (2001) Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of
tumor cells. Biochem Biophys Res Commun 282: 671-677.
70. Nagavarapu U, Relloma K, Herron GS (2002) Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous
epidermal cells. J Invest Dermatol 118: 573-581.
71. Ala-aho R, Johansson N, Grénman R, Fusenig NE, López-Otín C, et al. (2000) Inhibition of collagenase-3 (MMP-13) expression in transformed human
keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene 19: 248-257.
72. Ma Z, Qin H, Benveniste EN (2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical
role of STAT-1alpha. J Immunol 167: 5150-5159.
73. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, et al. (2001) Treatment with low-dose interferon-alpha restores the balance between matrix
metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res 7: 2840-2853.
74. Mengshol JA, Mix KS, Brinckerhoff CE (2002) Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull’s-eye or missing the mark?
Arthritis Rheum 46: 13-20.
75. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, et al. (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of
tumor invasion. Cancer Res 62: 3335-3339.
76. Overall CM, Wrana JL, Sodek J (1989) Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression
in human fibroblasts by transforming growth factor-beta. J Biol Chem 264: 1860-1869.
77. Uría JA, Jiménez MG, Balbín M, Freije JM, López-Otín C (1998) Differential effects of transforming growth factor-beta on the expression of collagenase-1
and collagenase-3 in human fibroblasts. J Biol Chem 273: 9769-9777.
78. Overall CM (1995) Repression of tissue inhibitor of matrix metalloproteinase expression by all-trans-retinoic acid in rat bone cell populations:
comparison with transforming growth factor-beta 1. J Cell Physiol 164: 17-25.
79. Maria JG Jiménez, Milagros Balbín, Jesús Alvarez, Toshihisa Komori, Paolo Bianco, et al. (2001) A regulatory cascade involving retinoic acid,
Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone
formation. J Cell Biol 155: 1333–1344.
80. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, et al. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and
metastases. J Clin Invest 109: 1551-1559.
81. McGaha TL, Phelps RG, Spiera H, Bona C (2002) Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforminggrowth-factor-beta-mediated
Smad3 activation in fibroblasts. J Invest Dermatol 118: 461-470.
82. Simon C, Goepfert H, Boyd D (1998) Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV
collagenase secretion and in vitro invasion. Cancer Res 58: 1135-1139.
83. Johansson N, Ala-aho R, Uitto V, Grénman R, Fusenig NE, et al. (2000) Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by
transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J Cell Sci 113: 227-235.
84. Shin M, Yan C, Boyd D (2002) An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible
92-kDa type IV collagenase expression. Biochim Biophys Acta 1589: 311-316.
85. Futamura M, Kamiya S, Tsukamoto M, Hirano A, Monden Y, et al. (2001) Malolactomycin D, a potent inhibitor of transcription controlled by the Ras
responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene 20: 6724-6730.
86. Zhang Y, Thant AA, Machida K, Ichigotani Y, Naito Y, et al. (2002) Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a
human lung carcinoma cell line QG90. Cancer Res 62: 3962-3965.
87. Karin M, Chang L (2001) AP-1--glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol 169: 447-451.
88. Sato T et al. (2002) Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid,
results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in
human fibrosarcoma HT-1080 cells. Cancer Res 62: 1025–1029.
89. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, et al. (2000) Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2,
including expression of matrix metalloproteinase gelatinase B. J Biol Chem 275: 10405-10412.
90. Bond M, Baker AH, Newby AC (1999) Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal
fibroblasts. Biochem Biophys Res Commun 264: 561-567.
OMICS Group eBooks
017